Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Gains from Sales and Divestitures (2023 - 2026)

Harmony Biosciences Holdings recorded quarterly Gains from Sales and Divestitures of $180279.0 in Q1 2026, down 16.46% quarter-over-quarter from $215795.0 in Q4 2025, and up 48.35% year-over-year from $121521.0 in Q1 2025.

Harmony Biosciences Holdings' Gains from Sales and Divestitures history runs 4 years deep, the most recent figure standing at $180279.0 for Q1 2026.

  • In Q1 2026, Gains from Sales and Divestitures rose 48.35% year-over-year to $180279.0; the TTM figure through Mar 2026 stood at $180279.0 (up 48.35% YoY), while the FY2025 annual figure was $215795.0, up 59.85% from the prior year.
  • Gains from Sales and Divestitures came in at $180279.0 for Q1 2026 at Harmony Biosciences Holdings, down from $215795.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $215795.0 in Q3 2025 to a low of $15000.0 in Q1 2024.
  • A 4-year average of $101860.4 and a median of $121521.0 in 2025 frame the typical range for Gains from Sales and Divestitures.
  • Across the five-year window, Gains from Sales and Divestitures tumbled 50.0% in 2024 and surged 1038.63% in 2025, its largest moves.
  • Harmony Biosciences Holdings' Gains from Sales and Divestitures stood at $30000.0 in 2023, then jumped by 350.0% to $135000.0 in 2024, then surged by 59.85% to $215795.0 in 2025, then decreased by 16.46% to $180279.0 in 2026.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods registered $180279.0, $215795.0, and $215795.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Harmony Biosciences Holdings 1.83 Bn 1.19 Bn 170.88 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 180,279.00
Mar 31, 2026 180,279.00
Dec 31, 2025 215,795.00
Dec 31, 2025 215,795.00
Sep 30, 2025 215,795.00
Sep 30, 2025 215,795.00
Jun 30, 2025 170,795.00
Jun 30, 2025 170,795.00
Mar 31, 2025 121,521.00
Mar 31, 2025 121,521.00
Dec 31, 2024 135,000.00
Dec 31, 2024 135,000.00
Sep 30, 2024 135,000.00
Sep 30, 2024 135,000.00
Jun 30, 2024 15,000.00
Jun 30, 2024 15,000.00
Mar 31, 2024 15,000.00
Mar 31, 2024 15,000.00
Dec 31, 2023 30,000.00
Dec 31, 2023 30,000.00
Sep 30, 2023 30,000.00
Sep 30, 2023 30,000.00
Jun 30, 2023 30,000.00
Jun 30, 2023 30,000.00
Mar 31, 2023 30,000.00
Mar 31, 2023 30,000.00